206 results about "Hepatitis B virus" patented technology

The invention relates to the field of immunology, and particularly discloses a hepatitis B virus specific TCR combination and application, the hepatitis B virus specific TCR combination is used for recognizing HBV antigen epitopes, the hepatitis B virus specific TCR combination comprises a plurality of separated TCRs, the plurality of separated TCRs form two TCR groups, and the two TCR groups comprise a first TCR group and a second TCR group; wherein the first TCR group specifically recognizes a first antigen epitope, and the amino acid sequence of the first antigen epitope is as shown in SEQ ID NO: 1; the first TCR group specifically recognizes a first antigen epitope, the second TCR group specifically recognizes a second antigen epitope, the amino acid sequence of the second antigen epitope is shown as SEQ ID NO: 2, the second antigen epitope respectively and correspondingly recognizes different antigen epitopes, the hepatitis B virus specific TCR and the epitope thereof are screened out, and an important means can be provided for treatment of TCR-T immune cells infected by hepatitis B virus.

The present invention relates generally to compositions, systems and methods for modulating hepatitis B virus (HBV) by targeting gene repression. In particular, the present invention provides an epigenetically modified DNA targeting system, such as a CRISPR-Cas / guide RNA (gRNA) system, for transcriptional repression of hepatitis B virus genes to promote cell phenotypes that lead to reduced HBV infection. In some embodiments, the epigenetically modified DNA targeting systems of the present invention bind to or target a target site of at least one gene in the hepatitis B virus DNA sequence or a regulatory element thereof in a cell. In some aspects, the systems provided herein relate to transcriptional repression of one or more hepatitis B virus genes and / or regulatory elements thereof. In some aspects, the invention also provides methods and uses associated with the provided compositions, such as in repression of hepatitis B virus replication and expression associated with hepatitis B infection.

The invention discloses a hepatitis B virus monoclonal neutralizing antibody SY-4 as well as preparation and application thereof. The hepatitis B virus monoclonal neutralizing antibody is SY-4 and consists of a heavy chain and a light chain paired with the heavy chain, the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the heavy chain of the SY-4 are DFSFSSHA, ISSYDGGTT and AKEGNAFRYFGWLPDYQYFGMDV in sequence, and the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the light chain of the SY-4 are QRINSRY, AAS and QQYGNSPLCS in sequence. The hepatitis B virus monoclonal neutralizing antibody SY-4 provided by the invention is an HBV neutralizing antibody, has ADCP activity, can crossly recognize various HBV genotypes HBsAg, has a good biological function, and provides a new candidate antibody for prevention and treatment of hepatitis B virus.

The present disclosure encompasses a lipid nanoparticle (LNP) comprising a polypeptide comprising a nucleic acid sequence encoding an engineered meganuclease that binds and cleaves a recognition sequence within a Hepatitis B virus (HBV) genome. Further, the disclosure encompasses pharmaceutical compositions comprising the LNPs, and the use of such compositions for inactivating a pol gene of an HBV genome or an HBV genome fragment in a cell and treating HBV infections or diseases associated with HBV infections.

This disclosure provides an immunoassay with exceptional sensitivity for detecting a target antigen in a sample. In one disclosure, the capture and detection steps of such an assay utilize recombinant antibodies. The disclosed immunoassay may find specific applications in the detection of HBV antigen.

The present application discloses the use of TIAR inhibitors for treating hepatitis B virus infection. The present application demonstrates that the host factor TIAR promotes HBV replication by regulating the translation of pgRNA through its binding, i.e. inhibiting the translation of nucleocapsid protein but promoting the translation of Pol. It is also found that TIAR is also packaged into the nucleocapsid of HBV through its binding to pgRNA. The present application provides a new solution for treating HBV infection based on TIAR as a target by reducing the expression of TIAR or inhibiting the binding of TIAR to pgRNA to inhibit HBV replication.

Disclosed herein is a novel tool to associate protein cargo molecules to the inside and / or outside of a Hepatitis B Virus (HBV) virus-like particle (VLP). The novel tool being composed of a sulfamoylbenzamide (SBA) antiviral, linker, and protein.

The present disclosure provides methods for treating HBV infection using combination therapies, and related kits and compositions for use. The components of the combination therapies may include one or more of an anti-HBV antibody; an siRNA that targets an HBV mRNA; interferon-α; and a nucleos(t)ide reverse transcriptase inhibitor (NRTI).

An antisense oligonucleotide and the use thereof. A series of ASOs are designed on the basis of the genome sequence of a hepatitis B virus (HBV), and are modified by means of using a specific modification mode. Cell and animal experiment results show that some modified ASOs obtained by means of using the specific modification mode can significantly reduce the expression of one or more HBV genes and block the life cycle of viruses, and therefore can be used to develop drugs for treating HBV infection-related diseases.

An endocyclic thiamidoamide-arylamide compound and a pharmaceutical composition comprising said compound are described, as well as the use of the same or of the pharmaceutical composition in the treatment of hepatitis B. In particular, a compound that can be used as an inhibitor of HBV replication and that has the structure shown in chemical formula (L), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, is described.

The invention relates to a reagent, a kit and a method for quantitative detection of HBV (hepatitis B virus) nucleic acid, specifically, the preparation comprises (a) a first upstream primer with a nucleotide sequence as shown in SEQ ID NO: 1, a first downstream primer with a nucleotide sequence as shown in SEQ ID NO: 2 and a first probe with a nucleotide sequence as shown in SEQ ID NO: 3; and / or (b) a second upstream primer with a nucleotide sequence as shown in SEQ ID NO: 4, a second downstream primer with a nucleotide sequence as shown in SEQ ID NO: 5 and a second probe with a nucleotide sequence as shown in SEQ ID NO: 6. The detection reagent, kit or method disclosed by the invention is good in specificity, high in sensitivity and complete in gene coverage and has an excellent effect on a large-volume sample.

Provided herein are antisense oligonucleotides and compositions that include the disclosed ASOs. The disclosed ASOs and compositions can be used for treating hepatitis B.

The present invention provides compositions and methods for novel digital PCR (dPCR) assay designs (droplet digital or other systems) for the detection and quantification of multiple Hepatitis B virus (HBV) gene targets. The compositions and methods can further include a non-extendible blocker oligonucleotide to reduce nonspecific inter-amplicon extension.

The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.

This invention discloses a kit for in vitro quantitative detection of hepatitis B virus large surface protein (LHBS). This kit includes multiple monoclonal antibodies, each with its own binding specificity to specific regions of LHBS, thereby improving the sensitivity and dynamic range of LHBS detection in biological samples. Secondly, this invention also provides a set of biological markers targeting specific regions of LHBS, and the monoclonal antibodies can specifically identify this set of biomarkers, enabling non-invasive analysis of HBV infection stages and liver cancer prognosis in biological samples. Furthermore, this invention also provides a set of monoclonal antibodies that, by detecting biomarkers in desired subjects, can predict, diagnose, or treat chronic liver disease.

The present disclosure relates to double stranded RNA agents targeting the hepatitis B virus (HBV) genome, and methods of using such agents to inhibit expression of one or more HBV genes and methods of treating subjects having an HBV infection or HBV-associated disorder, e.g., chronic hepatitis B infection.

The present disclosure includes synthetic methods for preparing certain substituted 1-aryl-1′-heteroaryl and 1,1′-biheteroaryl compounds, which can be used to treat, ameliorate, and / or prevent hepatitis B virus (HBV) infections in a patient.

The invention discloses a traditional Chinese medicine composition for treating fatty liver and reducing hepatitis B virus load. The traditional Chinese medicine composition is prepared from the following raw material medicines: prepared rehmannia root, rhizoma polygonati (processed), radix asparagi, schisandra chinensis, hawthorn leaf, glossy privet fruit, oriental wormwood, radix curcumae, illicium verum and salvia miltiorrhiza. According to the technology of the invention, liver treatment is a preparation based on compatibility of traditional Chinese medicine syndrome differentiation in which liver, spleen and kidney are treated at the same time, fat in the liver can be effectively removed, damage of hepatitis B virus to the liver can be reduced, hepatitis B virus reproduction can be effectively inhibited, the load of hepatitis B virus can be reduced, and multiple curative effects of liver treatment, liver nourishing and liver protection can be realized; the traditional Chinese medicine composition is superior to other treatment medicines and treatment technologies for fatty liver in modern medicine. The method can be widely applied to the fields of medicines, functional foods, health-preserving and health-care products, common foods and beverages and the like.

The application provides an RT-RAP primer probe set and kit for detecting blood viruses, and belongs to the technical field of molecular biology. The primer probe set comprises a primer probe set for detecting hepatitis B virus, and / or a primer probe set for detecting hepatitis C virus, and / or a primer probe set for detecting human immunodeficiency virus. The application adopts the detection means of RT-RAA and qPCR in sequence, and can simultaneously and rapidly detect hepatitis B virus, hepatitis C virus and human immunodeficiency virus in combination with the specific primer probe set, has higher sensitivity than ordinary qPCR, greatly shortens the reaction time, and has good specificity.

The invention discloses an application of a small molecule compound in inhibiting HBV (Hepatitis B Virus) replication and treating hepatitis B. According to the application of the small molecule compound C18H12F3N3OS in resisting hepatitis B virus (HBV) provided by the invention, systematic in-vitro and in-vivo experiments prove that the compound can effectively inhibit the replication and expression of the HBV through a multi-target action mechanism. Experimental data show that the compound can significantly reduce the total virus RNAs level in HBV infected cells and the expression level of HBVpgRNA and HBc proteins under the micromolar concentration, and can reduce the expression of HBeAg in a dose-dependent manner. The small molecule compound has the advantages of good chemical structure solubility and low toxicity (CC50gt; and the compound is expected to be applied to clinical transformation of anti-HBV drugs.

To provide a method for treating hepatitis B virus (HBV) infection in a subject.SOLUTION: Provided is a method comprising administering to the subject a single-dose pharmaceutical composition comprising an antibody having a specific sequence that binds to HBsAg.SELECTED DRAWING: Figure 3A

The invention discloses a digital PCR nucleic acid detection kit, and relates to the technical field of in vitro diagnosis detection, the kit comprises primers, probes, a reaction liquid and a quality control liquid, the kit is used for simultaneously detecting hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus and hepatitis E virus, the reaction liquid comprises Master Mix and sterile enzyme-free water, and the quality control liquid is used for simultaneously detecting the hepatitis A virus, the hepatitis B virus, the hepatitis C virus, the hepatitis D virus and the hepatitis E virus. The quality control liquid comprises a negative quality control product and a positive quality control product. Through cooperation of sample collection, sample treatment, digital PCR reaction system preparation, digital PCR amplification and result analysis, nucleic acid detection based on the PCR technology shortens the window period by 50-70% through direct detection of virus genetic materials, becomes a key means for early diagnosis, and adopts the technical principle of digital PCR to realize rapid detection of the virus genetic materials. Compared with a traditional fluorescent quantitative PCR and immunological detection method and a qPCR method, the detection sensitivity is improved by 10-100 times, and absolute quantification can be achieved.

This invention discloses a method for constructing a cancer assessment model, as well as a cancer assessment system, media, and electronic device. The assessment model developed in this invention significantly improves the diagnostic efficacy of hepatitis B virus-related liver cancer, especially demonstrating excellent predictive performance in early-stage liver cancer and patients with negative serum biomarkers. Compared with single biomarkers and existing scoring models, the cancer assessment model constructed in this invention has significant advantages in comprehensive indicators such as AUC, sensitivity, and specificity. Although GP73, introduced in the model, has a negative coefficient, its synergistic effect with other biomarkers effectively improves diagnostic performance. The assessment model constructed in this invention provides a reliable tool for non-invasive prediction and early screening of liver cancer, and has significant clinical application value.

Provided in the present application are a glycosylated fusion protein, a nucleic acid molecule, an expression vector, a host cell and the use thereof. A first aspect of the present application provides the glycosylated fusion protein, comprising a murine Fc variant and a hepatitis B virus antigen, wherein the murine Fc variant is obtained by performing amino acid mutation and non-mammalian glycosylation modification on a murine Fc fragment, the murine Fc variant comprises at least one of alanine at position 223, alanine at position 228, alanine at position 230, leucine at position 330, and glutamic acid at position 332, the glycosylation modification does not comprise sialic acid modification, and the positions are numbered according to the EU numbering system. The fusion protein can bind to DC cells and activate DC cells, and thus promote the proliferation and activation of specific T cells.

The present invention provides novel immunogenic peptides derived from the X and polymerase proteins of hepatitis B virus (HBV). These peptides contain epitopes that are well conserved among multiple HBV variants and are derived from regions of the proteins essential for viral replication. Furthermore, these novel HBV antigens bind to multiple HLA types and induce IFN-glucan synthesis in PBMCs from HBV-resolved individuals. γ Epitopes that elicit a response were identified.

In the field of Hepatitis B virus (HBV) detection, disclosed are a method for detecting HBcAg by means of using a double antibody sandwich method, and an antibody and kit for detecting HBcAg; also included is a monoclonal antibody that can be used in the immunological detection of HBcAg in a tissue or cell sample.

An object of the present invention is to provide a pharmaceutical composition useful as a novel anti-hepatitis B virus agent and a screening method. According to the present invention, there is provided a pharmaceutical composition that inhibits the production of a hepatitis B virus protein, in which the pharmaceutical composition inhibits the expression or the function of a protein belonging to the YTHDC family.

The invention features lentiviral transfer vectors that include heterologous nucleic acids to be introduced into a cell. The lentiviral transfer vector may be characterized by the following features: (a) including a cytomegalovirus (CMV) promoter; (b) including a polynucleotide encoding a partial gag protein that includes a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA; (c) not including a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag; (d) not including an SV40 origin of replication and / or an f1 origin of replication; (e) including a cPPT sequence that contains splice site; (f) including an EF1alpha promoter with intact splice donor and acceptor sites; and (g) including hepatitis B PRE with mutation in start codon of X protein ORF.

The present invention relates to a dual-target double-stranded RNA for treating hepatitis B, and a pharmaceutical composition. The dual-target double-stranded RNA comprises a first double-stranded RNA and a second double-stranded RNA, wherein one of the first double-stranded RNA and the second double-stranded RNA targets the hepatitis B virus (HBV) life cycle, and the other targets a host immune target PD-L1. The double-stranded RNA can simultaneously target the dual targets of HBV and host immune PD-L1, which can inhibit HBV replication while activating human immunity, and is therefore expected to bring about a clinical functional cure.